Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06744920RecruitingPhase 3
New drug for generalized myasthenia gravis
This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.
Phoenix, ArizonaAges 18–85 - NCT07225504RecruitingPhase 3
Study of remibrutinib for secondary progressive multiple sclerosis
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
Birmingham, AlabamaAges 18–65 - NCT07729579RecruitingPhase 1
Study of a drug for actinic keratosis on arms or face
This trial tests how a new drug works in people with actinic keratosis (rough, scaly patches caused by sun damage) on their upper arms or face. You will receive the treatment and have blood samples taken to see how your body processes the medication.
College Station, TexasAges 18–85 - NCT07369154RecruitingPhase 3
Safety of a long-term schizophrenia treatment
This study tests the long-term safety of an investigational medication for schizophrenia over one year. It may be an option if you are currently stable on your antipsychotic medication.
Chandler, ArizonaAges 18–65 - NCT07224373RecruitingPhase 1
A study of AZD0120 for multiple sclerosis
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
Tucson, ArizonaAges 18–60 - NCT05460000RecruitingPhase 2
Niraparib after early ovarian cancer chemo—short vs long
This trial tests whether taking niraparib (a maintenance anti-cancer pill) for a shorter time after 3 cycles of platinum chemotherapy works as well as taking it after 6 cycles. It is for people with advanced ovarian cancer that has been fully removed (no visible tumor) and is “HRD-positive,” meaning it has certain DNA repair weaknesses.
InnsbruckAges 18 years+ - NCT07260877RecruitingPhase 2
Testing VENT-03 for active skin lupus with or without systemic lupus
This study tests an experimental medicine called VENT-03 to see if it can improve skin lupus symptoms in adults. It compares VENT-03 against a placebo (a pill with no active drug) and includes a longer-term option where everyone can get the real drug. The goal is to find a new treatment for people whose lupus affects their skin.
Beverly Hills, CaliforniaAges 18–80 - NCT07726147RecruitingPhase 1
Testing a new allergy shot for Japanese cedar pollen
This trial tests a new allergy shot (ITI-9001) for people with Japanese cedar pollen allergy. It aims to see if the shot is safe and can reduce allergy symptoms. The study is for people who have not tried immunotherapy before.
Tokyo, Shinjuku-kuAges 1.5 years–65 years - NCT07637162Enrolling by invitationPhase 3
Safety study of AXS-14 for fibromyalgia
This study continues to monitor the safety of an investigational drug called AXS-14 in people with fibromyalgia who previously participated in another AXS-14 trial. Researchers want to make sure the treatment remains safe over time.
Arkansas City, ArkansasAges 18 years+ - NCT07373899Enrolling by invitation
Surgery after immunotherapy to shrink lung cancer
This study looks at whether doing surgery after immunotherapy (with or without chemo) can be less invasive than originally planned. If your lung cancer shrunk enough after treatment that you might need a smaller surgery than first thought, this trial could help find the best approach.
Beijing, ChaoyangAges Any age - NCT07573631Enrolling by invitationPhase 2
Long-term Safety Study of BMN 351 for Duchenne Muscular Dystrophy
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
Milan, ItalyAges 4 years+ - NCT07438405RecruitingPhase 2
Long-term safety study of AMG 732 for thyroid eye disease
This trial tests the long-term safety and effectiveness of AMG 732 for people with moderate-to-severe thyroid eye disease who have already completed an Amgen study of this drug. It allows continued treatment without needing immediate eye surgery.
Little Rock, ArkansasAges 18–99 - NCT07521852RecruitingPhase 2
New drug combination with immunotherapy for liver cancer
This trial tests a new drug called CVM-1118 combined with an immunotherapy drug (sintilimab) and a procedure called TACE (a catheter-based treatment that delivers medicine directly to tumors) in people with hepatocellular carcinoma (liver cancer) that cannot be cured by surgery. The goal is to see if this combination is effective and safe.
Fuzhou, FujianAges 18 years+ - NCT07008469Enrolling by invitationPhase 3
Long-term safety study of del-desiran for DM1
This study tests whether the drug del-desiran continues to be safe and effective for people with DM1 (myotonic dystrophy type 1) after they complete an earlier study. You'll receive the drug and have regular check-ups to see how you're doing.
Los Angeles, CaliforniaAges 16 years+ - NCT07720284RecruitingPhase 3
Testing new drugs for high-risk bladder cancer after surgery
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
Hot Springs, ArkansasAges 18 years+ - NCT07548996RecruitingPhase 2/Phase 3
Study of oral dimethyl fumarate for type 1 diabetes
This study tests an oral capsule called dimethyl fumarate to see if it can help preserve the body’s own insulin production in adults with type 1 diabetes. It may offer a way to slow the loss of beta cells and reduce reliance on insulin.
Nanjing, JiangsuAges 18–65 - NCT07101705RecruitingEarly Phase 1
Testing OriV508 for blood cancers that haven't responded to treatment
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT07436689Enrolling by invitationPhase 3
Long-term study of oral levosimendan for heart failure
This long-term study gives continued access to the oral levosimendan medication for people who finished the earlier TNX-103 study. The goal is to see if ongoing treatment remains safe and helpful.
Chicago, IllinoisAges Any age - NCT06858319RecruitingPhase 3
Long-term study of zigakibart for IgA nephropathy
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
Denver, ColoradoAges 18–100 - NCT06326905Recruiting
Transplant help for kidney waitlist patients with barriers
This study helps people on the deceased donor kidney waitlist who have had setbacks like health issues, lack of support, or low income. It offers extra support to help you get ready for transplant.
Baltimore, MarylandAges 18–99 - NCT06679270RecruitingPhase 3
Long-term safety study of metreleptin for partial lipodystrophy
This study tests the long-term safety of metreleptin for people with partial lipodystrophy. It is for those who already completed a related study and want to continue treatment.
Birmingham, AlabamaAges 13 years+ - NCT06997965RecruitingPhase 4
Mirikizumab for Crohn's with inflammatory strictures
This study tests a medication called mirikizumab to see if it can help people with Crohn's disease who have narrowing (strictures) in the small intestine caused by inflammation. The goal is to improve symptoms like belly pain after eating and to possibly reduce the narrowing without needing surgery.
Orlando, FloridaAges 18 years+ - NCT07627971RecruitingPhase 1/Phase 2
Gene therapy for GJB2-related hearing loss in young children
This study tests an experimental gene therapy (SKY-GJB2) designed to treat hearing loss caused by mutations in the GJB2 gene. The therapy is given directly to children ages 9 months to 7 years who have significant bilateral hearing loss, and researchers will monitor safety and whether hearing improves.
Boston, MassachusettsAges 9 months–7 years
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 367 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.